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Although the Pgp efflux transport protein is overexpressed in resected tissue of patients
with epilepsy, the presence of polymorphisms in MDR1/ABCB1 and MRP2/ABCC2 in
patients with antiepileptic-drugs resistant epilepsy (ADR) is controversial. The aim of this
study was to perform an exploratory study to identify nucleotide changes and search new
and reported mutations in patients with ADR and patients with good response (CTR) to
antiepileptic drugs (AEDs) in a rigorously selected population. We analyzed 22 samples
In Material and Methods, from drug-resistant patients with epilepsy and 7 samples from
patients with good response to AEDs. Genomic DNA was obtained from leukocytes. Eleven
exons in both genes were genotyped. The concentration of drugs in saliva and plasma
was determined. The concentration of valproic acid in saliva was lower in ADR than in
CRT. In ABCB1, five reported SNPs and five unreported nucleotide changes were iden-
tified; rs2229109 (GA) and rs2032582 (AT and AG) were found only in the ADR. Of six
SNPs associated with the ABCC2 that were found in the study population, rs3740066 (TT)
and 66744T>A (TG) were found only in the ADR. The strongest risk factor in the ABCB1
gene was identified as the TA genotype of rs2032582, whereas for the ABCC2 gene the
strongest risk factor was the T allele of rs3740066. The screening of SNPs in ACBC1 and
ABCC2 indicates that the Mexican patients with epilepsy in this study display frequently
reported ABCC1 polymorphisms; however, in the study subjects with a higher risk factor
for drug resistance, new nucleotide changes were found in the ABCC2 gene.Thus, the pop-
ulation of Mexican patients with AED-resistant epilepsy (ADR) used in this study exhibits
genetic variability with respect to those reported in other study populations; however, it is
necessary to explore this polymorphism in a larger population of patients with ADR.
Keywords: drug-resistant, epilepsy, ABCB1, ABCC2, Mexican patients, single-nucleotide polymorphisms,
anti-epileptic drugs
INTRODUCTION
Epilepsy is a chronic non-communicable disorder of the brain
that affects approximately 70 million people worldwide (1, 2).
The administration of anti-epileptic drugs (AEDs) is the treat-
ment of choice. In 30% of patients with epilepsy, seizures persist
despite polytherapy with more than one AED, adequate monitor-
ing of serum drug levels and the watchful care of a neurologist (3).
Hence, the timely identification of patients who do not respond
favorably to AEDs is crucial because these patients are affected
both by the treatment and by continuing seizures. Although the
pathophysiological basis of drug resistance in epilepsy is not clear,
some mechanisms for this resistance have been proposed. Follow-
ing seizures, the overexpression of drug-transporter proteins in the
blood brain barrier (BBB) could be mediated by the nuclear recep-
tor PXR (4); alternatively, polymorphisms in these proteins could
abrogate their function. The main function of carrier proteins is to
allow the passage of compounds through biological barriers such
as the BBB. Using ATP, the ABC transporter family of proteins
actively transports a wide variety of compounds, including toxins
and xenobiotics, across cell membranes. ABC transporter proteins
have two functional domains. The first domain is anchored to the
cell membrane by its alpha-helical structure; the second, which is
a nucleotide-binding domain (NBD), binds ATP, which provides
the energy necessary for the conformational change that result in
transport of the compound across the membrane. All ABC trans-
porters have at least two transmembrane domains and two NBDs
that are highly conserved between species (5).
MDR-1 (P-glycoprotein or P-gp) is an ATP-dependent efflux
pump protein that controls the flow of toxins and drugs such
as felbamate (FBM), gabapentin (GBP), lamotrigine (LTG),
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phenytoin (PTH), and topiramate (TPM) into the brain (6–9).
The gene encoding MDR-1 is ABCB1, which is located on chro-
mosome 7q21.12 and consists of 209,461 base pairs (bp) and 29
exons (NCBI reference sequence NG_011513.1). The most exten-
sively studied single-nucleotide polymorphisms (SNPs) in the
ABCB1 gene are rs1128503 (C1236T), rs2032582 (G2677T/A), and
rs1045642 (C3435T); the latter has received increased attention as
a critical variable in resistance to AEDs (10–16) MRP2 is another
efflux transporter protein present in the BBB. Its gene, ABCC2,
is located on chromosome 10q24 and contains 69,000 bp repre-
senting 33 exons (NG_011798.1). The MRP2 transporter protein
recognizes CBZ, LTG, and FBM; its most relevant polymorphisms
are rs2273697 (G1249A) and rs3740066 (C3972T). The latter poly-
morphism reduces the transport of carbamazepine (17–20). The
aim of this study was to perform a non-inferential exploratory
study to identify reported nucleotide changes and explore new
ones in a rigorously selected Mexican population of patients with
AED-resistant epilepsy (ADR) and patients with good response to
AEDs (CTR).
MATERIALS AND METHODS
PATIENTS AND SAMPLE COLLECTION
This project was approved by the National Research Committee
of the Instituto Mexicano del Seguro Social (Mexican Social Secu-
rity Institute, IMSS). An observational study with 22 patients with
ADR (cases) and 7 patients with good response to AEDs (controls)
was performed, while avoiding inbreeding between the patient’s
biological parents.
The inclusion criteria for ADR were patients with demon-
strable epileptic focus through EEG and radiological focal struc-
tural lesion to discard and classified as resistant to pharmaco-
logical treatment, treated with two or more drugs (Table 1) at
appropriate doses, serum levels within therapeutic range for at
least 6 months of continuous treatment, and under the super-
vision of a neurologist pediatrician, with a frequency of three
seizures per month, who attend Neurology Service, Hospital of
Pediatrics, National Medical Center, Century XXI, who is of
Mexican origin like their parents and grandparents, from 1 to
16 years of age, both genders, whereas for asymptomatic con-
trol patients was seizure-free for at least 6 months before the
study.
Both groups had complex partial seizures, showed similar clin-
ical variables, were previously selected under medical supervision,
and gave written informed consent. Exclusion criteria were all
types of seizures that are not complex partial, little adherence to
treatment.
A total of 15 ml of blood was collected from each patient via
antecubital vein using an EDTA tube, and two fractions of 0.5–
2.0 ml of saliva were collected upon stimulation with citric acid.
Samples that were used to monitor drug concentrations were taken
before the first dose in the morning.
AMPLIFICATION AND SEQUENCING
Genomic DNA was extracted from leukocytes in patient blood
samples using a commercial kit (Genomic DNA Purification kit,
Thermo Scientific®, USA), according to the supplier’s recommen-
dations. The polymorphisms (SNPs) from exons 1 (rs9282564), 10
Table 1 | Demographics and clinical data of patients with
AEDs-resistant epilepsy and patients with good response to AEDs.
Clinical data ADR CTR
Age (years±SD), range 10.45±3.762 (1–15) 11.50±3.017 (1–15)
Gender (F/M) 12/8 3/3
Onset of seizures 4.715±3.835 (1–14) 4.833±3.656 (2–10)
Number of seizures/month 63.45±27.76 (3–450) –
Years of seizures 5.85±0.8438 (1–12) –
Controlled time
(years±SD) range
– 1.9±0.28 (0.6–2)
Valproic Ac. dose
(mg/day)
598.0±129.7 814.3±212.1
Valproic Ac.
concentration/saliva (mg/l)
0.57±0.12 1.68±0.59
Valproic Ac.
concentration/plasma
(mg/l)
31.62±8.03 35.17±18.04
Carbamacepine dose
(mg/day)
900.0±100.0 600.0±200.0
Carbamacepine
concentration/saliva (mg/l)
0.7244±0.3232 1.017±0.034
Carbamacepine
concentration/plasma
(mg/l)
5.900±0.156 6.76±0.29
Phenytoin dose (mg/day) 145.0±55.00
Phenytoin
concentration/saliva (mg/l)
0.9337±0.06814
Phenytoin
concentration/plasma
(mg/l)
3.150±1.750
Levetiracetam dose
(mg/day)
1250±322.7 1000±0.0
Levetiracetam
concentration/saliva (mg/l)
1.661±0.8825
Levetiracetam
concentration/plasma
(mg/l)
4.657±0.5897
Mean±SD.
F, female; M, male.
(rs2229109), 11 (rs1128503), 13 (rs28381902), 20 (rs2032582), and
25 (rs1045642) were located in GenBank accession CCDS5608.1,
corresponding to the ABCB1 gene, and exons 10 (rs2273697),
25 (rs8187692, rs17222723), 28 (rs3740066), 29 (rs7899457), and
32 (rs8187710) were located in GenBank accession CCDS7484.1,
corresponding to the ABCC2 gene. These polymorphisms were
selected based on their frequency in the Hispanic or Mexican pop-
ulation, as noted in NCBI GenBank. Each amplification reaction
was performed with 5µl (5 ng/µl) of genomic DNA in a 50µl total
reaction volume containing 5µl of 10× reaction buffer, MgCl2
(concentration depending on the primer set), 1µl 10 mMdNTPs
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(Thermo Scientific®, USA), 1µl of each 10 mM flanking primer
(Invitrogen®, USA), and 1µl of Taq polymerase (Thermo Scien-
tific®, USA). PCR was performed in a DNA engine system®ther-
mocycler (Bio-Rad®, USA) with a cycle program at 94°C for 3 min,
38 cycles of 94°C for 30 s,T
◦
h for 35 s, 72°C for 35 s, and one exten-
sion cycle of 10 min at 72°C. The primers, MgCI2 concentration,
and T
◦
h for each amplification reaction are listed in Table 2.
The amplification products were purified with the GeneJET Gel
Extraction kit (Thermo Scientific®, USA) and sequenced in a 5µl
total reaction volume using 100 ng of amplicon, Fw or Rv primer,
and Big Dye 3.1 sequencing Ready Reaction Kit (Applied Biosys-
tems, USA) according to the manufacturer’s recommendations.
Sequencing was performed in a DNA engine system®thermocy-
cler (Bio-Rad®, USA) with a cycle program at 94°C for 1 min, 30
cycles of 94°C for 10 s, 50°C for 5 s, 60°C for 4 min, and finally the
fragments were analyzed in Automated Sequencing ABI Prism 310
Gene Analyzer (Applied Biosystems, USA), previous purification
with DyeEx 2.0 Spin Kit (Qiagen, Germany).
DRUG MONITORING
Plasma samples were used forVPA and CBZ detection by immuno-
fluorescence with a polarized light system (FPIA, Dade Behring,
USA), according to the supplier’s recommendations.
Saliva samples were used to detection concentration of CBZ and
PHT (determined by Axsym®, Abbot Laboratories®, USA) accord-
ing to the supplier’s recommendations,VPA, and LEV [determined
by high performance liquid chromatography (HPLC)]. For VPA,
30µl of an internal standard solution (98% octanoic acid diluted
1/500 with methanol), 200µl of phosphoric acid, and 5 ml of
cyclohexane were added to 1 ml of saliva and vortexed for 2 min.
After centrifugation, a back-extraction was performed by adding
100µl of 1% TEA to the organic phase supernatant. The mix-
ture was vortexed and centrifuged. Finally, 20µl of the aqueous
phase was directly injected into a Dionex Ultimate 3000 Series.
A Phenomenex Luna 5µm CN column (15 cm× 4.6 mm) was
used as the stationary phase. The mobile phase was a mixture
of 40 mM phosphate potassium, monobasic, pH 3.4: Acetonitrile
(90:10). The column compartment was kept at 40°C, and the wave-
length of detection was 210 nm. For LEV, 50µl of internal standard
solution (diethylbarbituric acid, 12 mg/l) was added to 500µl
of saliva. For the extraction, 1.5 ml of ethyl acetate was added,
and the mixture was vortexed for 1 min. After centrifugation,
the supernatant was separated and dried under nitrogen stream
at 37–40°C. Dry residue was dissolved with 100µl of mobile
phase, and 20µl was injected into a Shimadzu LC-6A.A Phe-
nomenex® Luna C18 column (5µm, 100 Å, 150 mm× 4.6 mm),
which was used as a reversed stationary phase. The mobile
phase was a mixture of 50 mM phosphate buffer and acetonitrile
(72:8).
STATISTICAL ANALYSIS
Clinical data from patients were analyzed using non-parametric
and unpaired tests (p< 0.05); allelic and genotype relative fre-
quencies were analyzed using the Fisher exact test in Graph Pad
Prism software version 4.00 (GraphpadPrisma Software Inc.® San
Diego, CA, USA). Hardy–Weinberg equilibrium (HWE) values
were derived from chi-square tests, and the association between
odds ratios (ORs) and confidence intervals was determined using
software available at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
RESULTS
CLINICAL DATA
Because previous studies suggest that external factors such as gen-
der, age of onset, number of seizures, and other factors influence
the response to AED treatment, the selection of a homogeneous
population for the study was an important aspect of this work
(21, 22). There was no significant difference in male: female
frequency between the two groups used in the study. Neither
the average age of the patients (10.57± 1.56 for patients with
good response to AEDs and 10.23± 0.78 for patients with ADR;
p= 0.42) or the average age of onset of seizures (4.57± 1.43 years
in patients with good response to AEDs and 4.38± 0.81 patients
with ADR; p= 0.34) differed significantly. Furthermore, the aver-
age seizure-free time in patients with good response to AEDs was
1.9 years, while the average time with seizures in patients with
ADR was 5.8 years with a frequency of 63.4 seizures per month.
The AEDs VPA, CBZ, LTG, PHT, and LEV were used with rela-
tive frequencies of 0.71, 0.14, 0.29, 0.0, and 0.14, respectively, in
patients with good response to AEDs and with relative frequen-
cies of 0.59, 0.09, 0.0, 0.18, and 0.23, respectively, in patients with
ADR. The most commonly used AED was VPA, but VPA and CBZ
were prescribed to both groups (Table 1). The daily dose of VPA
(814.3± 212.1 mg/day in patients with good response to AEDs and
598.0± 129.7 mg/day in patients with ADR;p= 0.206) was similar
in the two groups. The two groups showed no significant difference
in mean plasma VPA concentrations (35.17± 18.04 mg/l patients
with good response to AEDs and 31.62± 8.03 mg/l in patients
with ADR; p= 0.42); however, the average saliva drug concentra-
tion was lower in patients with ADR (1.68± 0.59 mg/l patients
with good response to AEDs and 0.57± 0.12 mg/l in patients with
ADR; p= 0.01).
POLYMORPHISMS IN THE ABCB1 AND ABCC2 GENES IN HISPANIC
AND MEXICAN POPULATIONS
In this study, chromatograms from amplicons were analyzed to
identify expected polymorphisms and to determine the relative
frequencies of alleles and genotypes, as described in Table 3.
For ABCB1, only the polymorphisms rs2229109, rs1128503,
rs28381902, rs2032582, and rs1045642, but not rs9282564, were
detected, whereas rs3740066 but not rs2273697, rs8187692,
rs17222723, rs7899457, or rs8187710 were found in ABCC2 in
our patients, unlike the Hispanic/Mexican populations initially
selected by the NCBI GenBank. In addition to these known poly-
morphisms, we identified rs2214102, rs2235047, and rs2235048 of
ABCB1 by sequencing the entire fragment including the exon and
parts of the introns.
Another comparison was made between the relative frequencies
of the minor allele (MAF) in our population and in the popula-
tion represented by the NCBI GenBank data. The most significant
similarities were found in rs1128503 and rs3740066 in ADR and
in rs1045642 and rs2235048 in CTR (Table 3).
An important aspect of genetic alteration is whether a
nucleotide change results in a change in an amino acid residue
and whether this, in turn, structurally modifies the protein. In
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Table 2 | Primers used on ABCB1 and ABCC2 fragments amplification.
GEN EXON Primer MgCl2 (mM) T oh Size (bp)
Fw RV
ABCB1 2 5′-AGGTTAGTCTCACCTCCAGCG-3′ 5′-GGCTAGCTTGCGTTTCTTAAA-3′ 1.0 57 270
11 5′-ATTCGAAGAGTGGGCACAAA-3′ 5′-TCATCTCACCATCCCCTCTGT-3′ 1.0 52 398
12 5′-ATTCGAAGAGTGGGCACAAA-3′ 5′-TCATCTCACCATCCCCTCTGT-3′ 1.0 52 398
14 5′-TTGGGCTGTGTATAGGATTCC-3′ 5′-AAGCCTCACTGACCTTATCCA-3′ 1.5 55 274
21 5′-CAGCATTCTGAAGTCATGGAA-3′ 5′-TCCAAGAACTGGCTTTGCTA-3′ 1.75 56 576
26 5′-TGTGCTGGTCCTGAAGTTGAT-3′ 5′-TGGTCGAACACTTTCATCCCT-3′ 1.50 62 472
ABCC2 10 5′-TTAGGCATTGACCCTATCCA-3′ 5′-GCCCAAACTCCCATTAAGAA-3′ 1.25 56 366
25 5′-CGGGACTGGCTGATTCTTTA-3′ 5′-ATGGGTAAATACCCAGGGGAA-3′ 1.0 54 273
28 5′-TTCTATGACACGAGTCCTGGG-3′ 5′-CATCCAGGCCTTCCTTCACT-3′ 1.25 56 258
29 5′-CCCCAAGAATTATTTGTGGAA-3′ 5′-GCATGTGCCCGAGTAAGTT-3′ 1.5 57 238
32 5′-GCCTAGACTTGAGATGCTGC-3′ 5′-TGGGGCCTTCTGCTAGAATT-3′ 1.5 55 198
The primer design was performed using the web page http://www.yeastgenome.org/cgi-bin/web-primer, T oh were selected by a temperature gradient, and MgCl2
concentration was selected initially with 2.0 mM and performed gradually until obtained a single sharp band.
this respect, the SNPs rs2229109 and rs2032582 are of interest due
to the possible modifications that they may produce in protein
MDR1 (Table 3).
The relative frequencies of the studied alleles were also com-
pared with their frequencies in the Hispanic and Mexican reference
populations reported in the NCBI GenBank (Table 4). In our pop-
ulation, SNP rs2229109 in exon 10 of ABCB1 occurred with a
relative frequency of 0.09 and was only present in heterozygous
form in the ADR group (Table 3). Although a reference for the
Mexican population was not available, we observed that our results
showed a twofold higher minor allele frequency with respect to
sample ss48292345 from the Hispanic population (0.043) in a
similar number of individuals (Table 4). The SNPs rs1128503
and rs2032582 in exons 11 and 20, respectively, of the ABCB1
gene showed similar relative frequencies in the CTR (0.71) and
ADR (0.82) patient groups; however, there was a difference in
the frequencies of homozygotes and heterozygotes in the CTR
group (Table 3). Furthermore, there were no Mexican individ-
uals with AG heterozygous mutations in SNP rs2032582, and
the AT heterozygous mutation was absent from both populations
(Table 4).
In studies of patients with ADR, SNP rs1045642 in exon 25 has
been shown to be relevant in association studies with drug resis-
tant; in our population, the relative frequencies of this SNP were
similar in the CTR and ARE groups at both the allelic and the
genotypic levels. Furthermore, the SNPs rs2235047 and rs2235048
were identified in an intron between exons 25 and 26. The het-
erozygous form of rs2235047 showed a higher frequency ADR
than in CTR (0.400 vs. 0.286), as seen in Table 3; however, the
most outstanding difference in this SNP was in comparison to ref-
erence populations, relative to which it was more than three times
as frequent (Table 4); this is more significant in our population
than rs1045642. The relative frequency of SNP rs2235048 was the
same as that of rs1045642; when SNP rs1045642 showed the TT,
TC, or CC genotype, we found the genotype CC, CT, or TT, respec-
tively, in the position of SNP rs2235048. This association may be
relevant to our population, which so far has not shown a clear
similarity to reference populations.
SNP rs3740066 in exon 28 of the ABCC2 gene occurred with
a relative frequency of 0.13 as a heterozygous polymorphism
in the controlled group and with a relative frequency of 0.41
as homozygous and heterozygous polymorphisms in the drug-
resistant group; the observed heterozygous ratio (ADR: CTR) was
2:1. In addition, the unexpected SNP rs2214102 located in the
5′UTR region of the ABCB1 gene was present in the homozygous
form in both groups; only 5% of the drug-resistant patients had the
heterozygous form. However, this finding is not relevant because
it is similar to a previous report in a Mexican population.
Some other differences observed in this study are worth not-
ing. At SNP rs2032582, the allelic and genotypic distribution in
the controlled group was more similar to reported populations
in NCBI GenBank than was that of the ADR; in particular, the
heterozygous A>T mutation was not found in other populations
similar to ours. Furthermore, although allele A of SNP rs2229109
was present at a lower frequency, our population showed an allele
frequency more than 2.5-fold greater than the reported MAF
(0.045 vs. 0.017).
NEW POLYMORPHISMS OF THE ABCC2 GENE IN MEXICAN EPILEPTIC
PEDIATRIC PATIENTS
By sequencing amplicons from exons 28 and 29 of the ABCB1 and
ABCC2 genes, we found other single-nucleotide changes (SNCs)
that have not been reported in the NCBI GenBank database
(Table 2, RefSeqGene NG_011798.1). The SNC located in posi-
tion 66744T>G adjacent to rs3740066 in exon 28 is present as
a homozygous wild-type or heterozygous mutation, allowing the
formation of four different triplets: ATC, ATT, AGT, and AGC.
The ATC and ATT triplets, which show relative frequencies of
0.929 and 0.682 for triplet ATC and 0.071 and 0.205 for triplet
ATT in CTR and ADR, respectively, are not associated with an
amino acid change (Ile1324Ile). The AGT and AGC triplets pro-
duce an amino acid change (Ile1324Ser, Figure 1A); these occur
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Table 3 | Genotype and allelic relative frequencies of SNPs, MAF value, amino acid changes, and OR found inABCB1 andABCC2 genes.
Gene SNP Sample Allele
frequency
Genotype
frequency
MAF Protein association Odds ratio
aa, change Localization Allele Genotype
Heterozogous Homozygous
ABCB1 rs2214102 CTR G=1.000 G/G=1.000 A=0.040/88 5′UTR region [G]↔ [A], 2.446 [GG]↔ [GA], 2.692 [GG]↔ [AA], 0.385
ADR G=0.971 G/G=0.955
A=0.029 G/A=0.045
rs2229109 CTR G=1.000 G/G=1.000 A=0.017/36 400; G>A; Ser>Asn Cytoplasmatic; binding
site; Second domain
[G]↔ [A], 1.706 [GG]↔ [GA], 1.829 [GG]↔ [AA], 0.366
ADR G=0.955 G/G=0.909
A=0.045 G/A=0.091
rs1128503 CTR T=0.571 C/T=0.571 T=0.422/919 412; T>C; Gly>Gly Cytoplasmatic; beta
chain; second domain
[T]↔ [C], 1.543 [TT]↔ [TC], 1.200 [TT]↔ [CC], 3.000
C=0.429 T/T=0.286
C/C=0.143
ADR T=0.455 C/T=0.545
C=0.545 T/T=0.182
C/C=0.273
rs2032582 CTR G=0.500 G/T=0.429 A=0.340/741 893; T>A; Ser>Thr Cytoplasmatic;
Alfa-helix chain; third
domain
[T]↔ [A], 2.143 [TT]↔ [TA], 2.778 [TT]↔ [AA], 0.526
T=0.500 G/G=0.286 893; T>G; Ser>Ala
T/T=0.286 [T]↔ [G], 1.375 [TT]↔ [TG], 1.333 [TT]↔ [GG], 1.750
ADR G=0.523 G/T=0.364
T=0.409 G/G=0.318
A=0.068 T/T=0.182
A/G=0.045
A/T=0.091
rs1045642 CTR T=0.429 TT=0.143 T=0.397/864 1145; T>C Ile> Ile Cytoplasmatic, fourth
domain
[T]↔ [C], 0.825 [TT]↔ [TC], 0.500 [TT]↔ [CC], 0.600
C=0.571 TC=0.571
CC=0.286
ADR T=0.475 TT=0.255
C=0.525 TC=0.450
CC=0.300
rs2235047 CTR T=0.857 TT=0.714 G=0.179/389 Intron between 25 and 26 exon [T]↔ [G], 1.020 [TT]↔ [TG], 1.026 [TT]↔ [GG], 0.407
G=0.143 TG=0.286
ADR T=0.800 TT=0.600
G=0.200 TG=0.400
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Table 3 | Continued
Gene SNP Sample Allele
frequency
Genotype
frequency
MAF Protein association Odds ratio
aa, change Localization Allele Genotype
Heterozogous Homozygous
rs2235048 CTR C=0.429 CC=0.143 C=0.398/867 Intron between 25 and 26 exon [C]↔ [T], 0.682 [CC]↔ [CT], 0.417 [CC]↔ [TT], 0.417
T=0.571 CT=0.571
TT=0.286
ADR C=0.525 CC=0.300
T=0.472 CT=0.450
TT=0.250
ABCC2 66744 T>G CTR T=1.000 T/T=1.000 No reported 1323; T>G; Ile>Ser Cytoplasmatic region,
fourth domain
[T]↔ [G], 4.038 [TT]↔ [TG], 4.1714 [TT]↔ [GG], 0.429
ADR T=0.890 T/T=0.770
G=0.110 T/A=0.230
rs3740066 CTR C=0.928 C/C=0.857 T=0.304/663 1324; C>T; Ile> Ile Cytoplasmatic region,
fourth domain
[C]↔ [T], 4.875 [CC]↔ [CT], 2.769 [CC]↔ [TT], 3.370
T=0.072 C/T=0.143
ADR C=0.727 C/C=0.591
T=0.273 C/T=0.273
T/T=0.136
68049 T>A CTR T=0.790 TT=0.570 No reported 1373; T>A; Leu>His Cytoplasmatic region,
fourth domain
[T]↔ [A], 0.733 [TT]↔ [TA], 0.667 [TT]↔ [AA], 0.310
A=0.210 TA=0.430
ADR T=0.840 TT=0.680
A=0.160 TA=0.320
67967C>A CTR C=0.500 CA=1.000 No reported 1342; C>A; Ser>Ser Cytoplasmatic region,
fourth domain
[C]↔ [A], 0.760 [CC]↔ [CA], 0.371 [CC]↔ [AA], 0.143
A=0.500
ADR C=0.570 CC=0.140
A=0.430 CA=0.860
68072C>A CTR C=0.500 CA=1.000 No reported 1381; C>A; Pro>Thr Cytoplasmatic region,
fourth domain
[C]↔ [A], 0.750 [CC]↔ [CA], 0.352 [CC]↔ [AA], 0.143
A=0.500
ADR C=0.590 CC=0.180
A=0.410 CA=0.820
68088 G>C CTR G=0.710 GG=0.710 No reported Intron between 29 and 30 [G]↔ [C], 0.147 [GG]↔ [GC], 0.314 [GG]↔ [CC], 0.147
C=0.290 CC=0.290
ADR G=0.890 GG=0.840
C=0.110 CC=0.160
Relative frequencies are presented for the five SNPs reported on NCBI Gene Bank database of ABCB1 and ABCC2 genes among 14 controlled and 44 drug-resistant patients (2n), obtained by direct sequencing.
The position indicates the nucleotide change at ABCC2 gene from RefSeqGene NG_011798.1. Amino acid change was obtained from SNP page and its localization from http:// www.uniprot.org/ website. Odds ratio
(OR) represent the allele risk or mutated using the software on line through the web page http:// ihg.gsf.de/ cgi-bin/ hw/ hwa1.pl . Bold font: allele OR>1.0. DR, drug-resistant; CTR, controlled; MAF, Minor Allele
Frequency.
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Table 4 | Genotype and allelic population frequencies of SNPs found in ABCB1 and ABCC2 genes.
Gene SNP NCBI assay ID Population Sample (2n) Allele frequency Genotype frequency
ABCB1 rs2235048 ss35072278 Hispanic 44 T=0.455 TT=0.182
C=0.545 TC=0.545
CC=0.273
ss48292340 Hispanic 38 T=0.553 TT=0.369
C=0.447 TC=0.368
CC=0.263
ss44833502 Mexican 100 T=0.540 TT=0.260
C=0.460 TC=0.560
CC=0.180
rs2235047 ss35072277 Hispanic 44 T=0.932 TT=0.864
G=0.068 TG=0.136
Mexican 100 T=0.900 TT=0.840
G=0.100 TG=0.126
GG=0.011
ss48292339 Hispanic 42 T=0.952 TT=0.905
G=0.048 TG=0.095
GG=0.00
rs1045642 ss35072275 Hispanic 42 T=0.452 TT=0.238
C=0.548 TC=0.429
CC=0.333
Mexican 100 C=0.540 TT=0.180
T=0.460 TC=0.560
CC=0.260
rs2214102 ss12675208 Hispanic 46 G=0.957 G/G=0.913
A=0.043 A/G=0.087
ss35071953 Hispanic 44 G=0.905 G/G=0.810
A=0.095 A/G=0.190
ss52073858 Mexican 77 G=0.980 G/G=0.960
A=0.020 A/G=0.040
rs2229109 ss35072104 Hispanic 44 G=1.000 G/G=1.000
A=0.000 A/G=0.000
ss48292345 Hispanic 46 G=0.978 G/G=0.957
A=0.022 A/G=0.043
rs1128503 ss35072107 Hispanic 44 T=0.545 C/T=0.545
C=0.455 T/T=0.273
C/C=0.182
ss48292343 Hispanic 46 C=0.609 C/T=0.522
T=0.391 C/C=0.348
T/T=0.130
ss52068966 Mexican 77 C=0.540 C/T=0.560
T=0.460 C/C=0.260
T/T=0.180
rs2032582 ss12675210 Hispanic 46 G=0.565 G/T=0.522
T=0.392 G/G=0.261
A=0.043 T/T=0.130
A/G=0.08
ss35072218 Hispanic 44 G=0.545 G/T=0.636
T=0.455 G/G=0.227
T/T=0.136
ss12675210 Mexican 77 G=0.570 G/T=0.540
T=0.430 G/G=0.300
T/T=0.160
(Continued)
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Table 4 | Continued
Gene SNP NCBI assay ID Population Sample (2n) Allele frequency Genotype frequency
ABCC2 rs3740066 ss48292395 M 44 C=0.614 C/T=0.500
T=0.386 C/C=0.364
T/T=0.136
Hispanic populations from ss12675208, ss48292345, ss48292343, ss12675210, and ss48292395 samples belong to HISP-MULTI-NATIONAL Population ID Class,
obtained of 23 anonymized individuals of self-described HISPANIC heritage. Hispanic populations from ss35071953, ss35072104, ss35072107 and ss35072218 sam-
ples belong to EGP_HISP-PANEL Population ID Class, obtained of 22 individuals with Coriell Cell Repository (CCR) ID. Mexican population belongs to HAPMAP-MEX
Population ID Class, obtained of 100 individuals with Mexican ancestry in Los Angeles, California.
at relative frequencies of 0.068 and 0.045, respectively, but only in
drug-resistant patients.
For the SNC 67967C>A in exon 29, no amino acid
change (Ser1342Ser) was observed due to nucleotide substitution
(Figure 1B); however, SNC 68072C>A resulted in the amino
acid change Pro1381Thr (Figure 1D). This allele was present as a
heterozygous mutation in both groups (1.0 in the CTR group, 0.86
in the ADR group). The SNC 68049T>A in exon 29 resulted in a
Leu1373His change (Figure 1C); this allele was heterozygous (0.43
in the CTR group, 0.32 in the ADR group), but the wild-type allele
predominated in both groups (>50%). These nucleotide changes
are located in the region of the gene coding for the fourth domain
of the protein, corresponding to its cytoplasmic region. In con-
trast, the SNC 68088G>C (Figure 1E), which is located between
exons 29 and 30, occurred in our study population as a homozy-
gous mutation with a relative frequency of 0.29 in the CTR group
and a relative frequency of 0.05 in ADR group.
DISCUSSION
The pediatric epilepsy patients admitted to the Neurology Ser-
vice, Hospital of Pediatrics, National Medical Center, Century XXI,
were referred from family clinics and general hospitals for inad-
equate control of epileptic seizures. In most cases, the patients
received dosage adjustments or changes in drug regimen, drug
monitoring, and electroencephalographic studies and were fol-
lowed closely for adequate control of their seizures. However, some
patients continued to interictal epileptiform discharges on EGG
and/or the occurrence of seizures, and some gradually deterio-
rated. The results obtained with a small group of patients who
did not respond to at least three different drug regimens but
were followed for 4.7± 3.8 (CI= 1–14) years are presented in
this work.
Fagiolino et al. (23) suggested that the quantitation of drugs in
saliva can be used to identify drug-resistant patients. The hypoth-
esis presented by these authors is based on the drug concentration
circulating in free plasma, which irrigates the glandular capillary
tissue, resulting in equilibrium with the aqueous spaces. Consid-
ering our results with respect to this hypothesis, we found a lower
concentration of free VPA in drug-resistant patients, suggesting a
possible deficiency in drug transport in these patients.
The overexpression of P-gp and MRP2 in resected tissue from
patients who have undergone surgery for epilepsy suggests that
this phenomenon may be conditional upon the presence of poly-
morphisms in the genes ABCB1 and ABCC2 and not simply to
exposure to xenobiotics that recognize these transporter proteins.
However, the association between polymorphisms of the ABCB1
and ABCC2 genes and anti-epileptic drug-resistant epilepsy is
controversial; SNPs rs1128503 (C1236T), rs2032582 (G2677T/A),
and especially rs1045642 (C3435T) in the ABCB1 gene have
not shown a clear relationship to anti-epileptic drug-resistant
epilepsy from different populations or ethnic groups (13, 24–
27). This may be because, as has been reported, SNP rs1045642
is more relevant as a haplotype with rs1128503 and rs2032582.
Zimprichet et al. (28), studying European patients with tem-
poral lobe epilepsy, demonstrated a relationship between the
CGC haplotype at SNPs rs1128503, rs2032582, and rs1045642,
respectively, and resistance to several AEDs. In another report,
Seo et al. (10) demonstrated that Japanese with anti-epileptic
drug-resistant epilepsy showed a tendency to possess the haplo-
type TTT at SNPs rs1128503, rs2032582, and rs1045642 when
CBZ was employed. To enable comparison with those reports,
haplotype frequency was calculated in our population. Both
haplotypes (CGC and TTT) were found in our population.
Within each group, the two haplotypes occurred with similar fre-
quencies (CGC= 0.619, TTT= 0.523 in ADR and CGC= 0.714,
TTT= 0.714 in CTR), but both were present at higher frequencies
in the CTR group.
For patients who exhibit a mutated allele, OR values can
be used to represent relative risk factors among the ADR and
CTR patients. The polymorphisms or nucleotide changes, in
descending order of risk factor magnitude, are rs2214102>
rs2032582 [T↔A]> rs2229109> rs1128503> rs2032582 [T↔
G]> rs2235047 in ABCB1, and rs3740066> 66744 T>G
in ABCC2; relative to heterozygote genotype rs2032582
[T↔A]> rs2214102> rs2229109> rs2032582 [T↔G]> rs11
28503> rs2235047 in ABCB1, and 66744 T>G> rs3740066
in ABCC2; finally, with regard to the homozygote genotype,
rs1128503> rs2032582 [T↔G] in ABCB1 and rs3740066 in
ABCC2 (Table 3).
Although the number of patients is lower in our work, the
results are similar to studies with larger numbers of patients (25,
29, 30), where the lack of association of ABCB1 polymorphisms
with anti-epileptic drug resistance (indicated by us as a risk fac-
tor) it has been pointed out, including two Indian studies (31, 32)
and a meta-analysis (26). In contrast, Taur et al. (33) and Siddiqui
et al. (34) reported association with anti-epileptic drug resistance.
On the other hand, we find that the ABCC2 is a greater risk factor
for increased anti-epileptic drug resistance than ABCB1, although
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FIGURE 1 | Chromatograms of single-nucleotide changes found
in theABCC2 gene from Mexican pediatric patients with
epilepsy. (A) The 66744 T>G change in located in exon 28. (B) The
67967 C>A change in located in exon 29. (C) The 68049 T>A
change in located in exon 29. (D) The 68072 C>A change in located
in exon 29. (E) The 68088 G>C change in located in intron 29. The
position indicates the nucleotide change in the ABCC2 gene
(RefSeqGene NG_011798.1).
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in previous studies, we only share the SNP rs3740066, not repre-
senting a major risk factor as the high activity promoter variant
c-24C>T; these data suggest that ABCC2 polymorphism may
affect the response to AEDs.
This study employed a different strategy, rigorously select-
ing pediatric patients with ADR and patients with good seizure
control to decrease the potential influence of confounding
variables associated with the disease, to develop a study utilizing
a non-inferential exploratory search based on the polymorphisms
already reported and on unreported new characteristics of the
Mexican population. Because our population has been little stud-
ied, this will allow us to conduct association studies with new
SNPs and AEDs used to treat different forms of epilepsy. To
avoid sequencing entire genes, we selected exons containing poly-
morphisms that have been previously reported in Mexican and
Hispanic populations, including the P-gp and MRP2 proteins,
which are associated with drug resistance. The most important
outcome of this study was the identification of five new changes
in the ABCC2; these are 66744T>G, 67967C>A, 68072C>A,
68049C>A, and G68088C. The nucleotide change 66744T>G
was found only in ADR, and the risk factor associated with it was
one of the highest found in the study. Moreover, the genetic vari-
ability in SNP rs2032582 in ADR was different and unexpected
based on previous reports in the Mexican population in that the
A allele was found. This result requires replication in a larger pool
of Mexican patients.
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